<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35701899</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1789</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neuropathology : official journal of the Japanese Society of Neuropathology</Title><ISOAbbreviation>Neuropathology</ISOAbbreviation></Journal><ArticleTitle>Praja1 RING-finger E3 ubiquitin ligase is a common suppressor of neurodegenerative disease-associated protein aggregation.</ArticleTitle><Pagination><StartPage>488</StartPage><EndPage>504</EndPage><MedlinePgn>488-504</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/neup.12840</ELocationID><Abstract><AbstractText>The formation of misfolded protein aggregates is one of the pathological hallmarks of neurodegenerative diseases. We have previously demonstrated the cytoplasmic aggregate formation of adenovirally expressed transactivation response DNA-binding protein of 43&#x2009;kDa (TDP-43), the main constituent of neuronal cytoplasmic aggregates in cases of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), in cultured neuronal cells under the condition of proteasome inhibition. The TDP-43 aggregate formation was markedly suppressed by co-infection of adenoviruses expressing heat shock transcription factor 1 (HSF1), a master regulator of heat shock response, and Praja1 RING-finger E3 ubiquitin ligase (PJA1) located downstream of the HSF1 pathway. In the present study, we examined other reportedly known E3 ubiquitin ligases for TDP-43, i.e. Parkin, RNF112 and RNF220, but failed to find their suppressive effects on neuronal cytoplasmic TDP-43 aggregate formation, although they all bind to TDP-43 as verified by co-immunoprecipitation. In contrast, PJA1 also binds to adenovirally expressed wild-type and mutated fused in sarcoma, superoxide dismutase 1, &#x3b1;-synuclein and ataxin-3, and huntingtin polyglutamine proteins in neuronal cultures and suppressed the aggregate formation of these proteins. These results suggest that PJA1 is a common sensing factor for aggregate-prone proteins to counteract their aggregation propensity, and could be a potential therapeutic target for neurodegenerative diseases that include ALS, FTLD, Parkinson's disease and polyglutamine diseases.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Neuropathology published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Society of Neuropathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watabe</LastName><ForeName>Kazuhiko</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0245-3834</Identifier><AffiliationInfo><Affiliation>Department of Medical Technology (Neuropathology), Faculty of Health Sciences, Kyorin University, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pathological Neuroscience, Department of Pathology, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niida-Kawaguchi</LastName><ForeName>Motoko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pathological Neuroscience, Department of Pathology, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Psychology, Faculty of Health Sciences, Kyorin University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tada</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Yoichiro</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0777-5020</Identifier><AffiliationInfo><Affiliation>Division of Pathological Neuroscience, Department of Pathology, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murata</LastName><ForeName>Makiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Technology (Neuropathology), Faculty of Health Sciences, Kyorin University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanji</LastName><ForeName>Kunikazu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wakabayashi</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-3756-7209</Identifier><AffiliationInfo><Affiliation>Department of Neuropathology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Mitsunori</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Neuropathology, Department of Brain Disease Research, Shinshu University School of Medicine, Matsumoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakita</LastName><ForeName>Akiyoshi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shibata</LastName><ForeName>Noriyuki</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-7173-5061</Identifier><AffiliationInfo><Affiliation>Division of Pathological Neuroscience, Department of Pathology, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>#18K06507</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country/></Grant><Grant><GrantID>2020-2021</GrantID><Agency>Niigata University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Neuropathology</MedlineTA><NlmUniqueID>9606526</NlmUniqueID><ISSNLinking>0919-6544</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076249">Heat Shock Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076249" MajorTopicYN="N">Heat Shock Transcription Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044767" MajorTopicYN="Y">Ubiquitin-Protein Ligases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Praja1</Keyword><Keyword MajorTopicYN="N">fused in sarcoma</Keyword><Keyword MajorTopicYN="N">superoxide dismutase 1</Keyword><Keyword MajorTopicYN="N">transactivation response DNA-binding protein of 43&#x2009;kDa</Keyword><Keyword MajorTopicYN="N">&#x3b1;-synuclein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35701899</ArticleId><ArticleId IdType="pmc">PMC10084124</ArticleId><ArticleId IdType="doi">10.1111/neup.12840</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prusiner SB. Biology and genetics of prions causing neurodegeneration. Annu Rev Genet 2013; 47: 601&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4010318</ArticleId><ArticleId IdType="pubmed">24274755</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del TK, Lee VM&#x2010;Y, Trojanowski JQ. Spreading of pathology in neurodegenerative diseases: A focus on human studies. Nat Rev Neurosci 2015; 16: 109&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4312418</ArticleId><ArticleId IdType="pubmed">25588378</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J, Yue Z. Neuronal aggregates: Formation, clearance, and spreading. Dev Cell 2015; 32: 491&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4376477</ArticleId><ArticleId IdType="pubmed">25710535</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourdenx M, Koulakiotis NS, Sanoudou D, Bezard E, Dehay B, Tsarbopoulos A. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. Prog Neurobiol 2017; 155: 171&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">26209472</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis AA, CEG L, Holtzman DM. Intercellular spread of protein aggregates in neurodegenerative disease. Annu Rev Cell Dev Biol 2018; 34: 545&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6350082</ArticleId><ArticleId IdType="pubmed">30044648</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat Neurosci 2018; 21: 1341&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375686</ArticleId><ArticleId IdType="pubmed">30258241</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng C, Trojanowski JQ, Lee VM. Protein transmission in neurodegenerative disease. Nat Rev Neurol 2020; 16: 199&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9242841</ArticleId><ArticleId IdType="pubmed">32203399</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, Groen EJ, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol 2013; 125: 777&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3661910</ArticleId><ArticleId IdType="pubmed">23673820</ArticleId></ArticleIdList></Reference><Reference><Citation>Berning BA, Walker AK. The pathobiology of TDP&#x2010;43 C&#x2010;terminal fragments in ALS and FTLD. Front Neurosci 2019; 13: 335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6470282</ArticleId><ArticleId IdType="pubmed">31031584</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer RC, Chami AA, Assis DRD, Vourc P, Andres CR, Corcia P. The debated toxic role of aggregated TDP&#x2010;43 in amyotrophic lateral sclerosis: A resolution in sight? Brain 2019; 142: 1176&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK. Molecular mechanisms of TDP&#x2010;43 misfolding and pathology in amyotrophic lateral sclerosis. Front Mol Neurosci 2019; 12: 25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Portz B, Lee BL, Shorter J. FUS and TDP&#x2010;43 phases in health and disease. Trends Biochem Sci 2021; 46: 550&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8195841</ArticleId><ArticleId IdType="pubmed">33446423</ArticleId></ArticleIdList></Reference><Reference><Citation>Keating SS, San Gil R, Swanson MEV, Scotter EL, Walker AK. TDP&#x2010;43 pathology: From noxious assembly to therapeutic removal. Prog Neurobiol 2022; 211: 102229. 10.1016/j.pneurobio.2022.102229</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2022.102229</ArticleId><ArticleId IdType="pubmed">35101542</ArticleId></ArticleIdList></Reference><Reference><Citation>Watabe K, Akiyama K, Kawakami E et al. Adenoviral expression of TDP&#x2010;43 and FUS genes and shRNAs for protein degradation pathways in rodent motoneurons in vitro and in vivo. Neuropathology 2014; 34: 83&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">23937386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Kawakami E, Endo K, Misawa H, Watabe K. Formation and spreading of TDP&#x2010;43 aggregates in cultured neuronal and glial cells demonstrated by time&#x2010;lapse imaging. PLoS One 2017; 12: e0179375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5466347</ArticleId><ArticleId IdType="pubmed">28599005</ArticleId></ArticleIdList></Reference><Reference><Citation>Watabe K, Kato Y, Sakuma M et al. Praja1 RING&#x2010;finger E3 ubiquitin ligase suppresses neuronal cytoplasmic TDP&#x2010;43 aggregate formation. Neuropathology 2020; 40: 570&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7818255</ArticleId><ArticleId IdType="pubmed">32686212</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebron ML, Lonskaya I, Sharpe K et al. Parkin ubiquitinates tar&#x2010;DNA binding protein&#x2010;43 (TDP&#x2010;43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6). J Biol Chem 2013; 288: 4103&#x2013;4115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3567661</ArticleId><ArticleId IdType="pubmed">23258539</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida T, Tamaki Y, Ayaki T et al. CUL2&#x2010;mediated clearance of misfolded TDP&#x2010;43 is paradoxically affected by VHL in oligodendrocytes in ALS. Sci Rep 2016; 6: 19118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707540</ArticleId><ArticleId IdType="pubmed">26751167</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YC, Huang WC, Lin JH et al. Znf179 E3 ligase&#x2010;mediated TDP&#x2010;43 polyubiquitination is involved in TDP&#x2010;43&#x2010; ubiquitinated inclusions (UBI) (+)&#x2010;related neurodegenerative pathology. J Biomed Sci 2018; 25: 76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6223059</ArticleId><ArticleId IdType="pubmed">30404641</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma P, Li Y, Wang H, Mao B. Haploinsufficiency of the TDP43 ubiquitin E3 ligase RNF220 leads to ALS&#x2010;like motor neuron defects in the mouse. J Mol Cell Biol 2021; 13: 374&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373269</ArticleId><ArticleId IdType="pubmed">33386850</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh B, Karmakar S, Prasad M, Mandal AK. Praja1 ubiquitin ligase facilitates degradation of polyglutamine proteins and suppresses polyglutamine&#x2010;mediated toxicity. Mol Biol Cell 2021; 32: 1579&#x2013;1593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8351749</ArticleId><ArticleId IdType="pubmed">34161122</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Kawakami E, Endo K, Misawa H, Watabe K. Myelinating cocultures of rodent stem cell line&#x2010;derived neurons and immortalized Schwann cells. Neuropathology 2017; 37: 475&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">28707715</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper PL, Durham HD, T&#xf6;r&#xf6;k Z, Hooper PL, Crul T, V&#xed;gh L. The central role of heat shock factor 1 in synaptic fidelity and memory consolidation. Cell Stress Chaperones 2016; 21: 745&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003801</ArticleId><ArticleId IdType="pubmed">27283588</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez&#x2010;Pastor R, Burchfiel ET, Thiele DJ. Regulation of heat shock transcription factors and their roles in physiology and disease. Nat Rev Mol Cell Biol 2018; 19: 4&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5794010</ArticleId><ArticleId IdType="pubmed">28852220</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wu J, Xu L, Wang J, Chen Z, Yang R. Regulation of HSF1 protein stabilization: An updated review. Eur J Pharmacol 2018; 822: 69&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">29341886</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HJ, Mitchell JC, Novoselov S et al. The heat shock response plays an important role in TDP&#x2010;43 clearance: Evidence for dysfunction in amyotrophic lateral sclerosis. Brain 2016; 139: 1417&#x2013;1432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4845254</ArticleId><ArticleId IdType="pubmed">26936937</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin PY, Folorunso O, Taglialatela G, Pierce A. Overexpression of heat shock factor 1 maintains TAR DNA binding protein 43 solubility via induction of inducible heat shock protein 70 in cultured cells. J Neurosci Res 2016; 682: 671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">26994698</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin PY, Simon SM, Koh WK, Folorunso O, Umbaugh CS, Pierce A. Heat shock factor 1 over&#x2010;expression protects against exposure of hydrophobic residues on mutant SOD1 and early mortality in a mouse model of amyotrophic lateral sclerosis. Mol Neurodegener 2013; 8: 43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3907013</ArticleId><ArticleId IdType="pubmed">24256636</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Ageta&#x2010;Ishihara N, Nagatsu S et al. SIRT1 overexpression ameliorates a mouse model of SOD1&#x2010;linked amyotrophic lateral sclerosis via HSF1/HSP70i chaperone system. Mol Brain 2014; 7: 62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4237944</ArticleId><ArticleId IdType="pubmed">25167838</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright GSA. Molecular and pharmacological chaperones for SOD1. Biochem Soc Trans 2020; 48: 1795&#x2013;1806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7458393</ArticleId><ArticleId IdType="pubmed">32794552</ArticleId></ArticleIdList></Reference><Reference><Citation>Liangliang X, Yonghui H, Shunmei E, Shoufang G, Wei Z, Jiangying Z. Dominant&#x2010;positive HSF1 decreases alpha&#x2010;synuclein level and alpha&#x2010;synuclein&#x2010;induced toxicity. Mol Biol Rep 2010; 37: 1875&#x2013;1881.</Citation><ArticleIdList><ArticleId IdType="pubmed">19609719</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilpatrick K, Novoa JA, Hancock T et al. Chemical induction of Hsp70 reduces &#x3b1;&#x2010;synuclein aggregation in neuroglioma cells. ACS Chem Biol 2013; 8: 1460&#x2013;1468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4532326</ArticleId><ArticleId IdType="pubmed">23594135</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim E, Wang B, Sastry N et al. NEDD4&#x2010;mediated HSF1 degradation underlies &#x3b1;&#x2010;synucleinopathy. Hum Mol Genet 2016; 25: 211&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4706110</ArticleId><ArticleId IdType="pubmed">26503960</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira&#x2010;Castro A, Ailion M, Jalles A et al. Neuron&#x2010;specific proteotoxicity of mutant ataxin&#x2010;3 in C. elegans: Rescue by the DAF&#x2010;16 and HSF&#x2010;1 pathways. Hum Mol Genet 2011; 20: 2996&#x2013;3009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3131043</ArticleId><ArticleId IdType="pubmed">21546381</ArticleId></ArticleIdList></Reference><Reference><Citation>McLoughlin HS, Moore LR, Paulson HL. Pathogenesis of SCA3 and implications for other polyglutamine diseases. Neurobiol Dis 2020; 134: 104635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980715</ArticleId><ArticleId IdType="pubmed">31669734</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez&#x2010;Pastor R, Burchfiel ET, Neef DW et al. Abnormal degradation of the neuronal stress&#x2010;protective transcription factor HSF1 in Huntington's disease. Nat Commun 2017; 8: 14405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5316841</ArticleId><ArticleId IdType="pubmed">28194040</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra L, Tully RE, Monga SP et al. Praja1, a novel gene encoding a RING&#x2010;H2 motif in mouse development. Oncogene 1997; 15: 2361&#x2013;2368.</Citation><ArticleIdList><ArticleId IdType="pubmed">9393880</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki A, Masuda Y, Iwai K, Ikeda K, Watanabe K. A RING finger protein Praja1 regulates Dlx5&#x2010;dependent transcription through its ubiquitin ligase activity for the dlx/Msx&#x2010;interacting MAGE/Necdin family protein, Dlxin&#x2010;1. J Biol Chem 2002; 277: 22541&#x2013;22546.</Citation><ArticleIdList><ArticleId IdType="pubmed">11959851</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoabi M, Sadeh R, Bie PD, Ciechanover A. PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins. Biochem Biophys Res Commun 2011; 408: 393&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">21513699</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra L, Katuri V, Evans S. The role of PRAJA and ELF in TGF&#x2010;beta signaling and gastric cancer. Cancer Biol Ther 2005; 4: 694&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">16096365</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha T, Vardhini D, Tang Y et al. RING finger&#x2010;dependent ubiquitination by PRAJA is dependent on TGF&#x2010;&#x3b2; and potentially defines the functional status of the tumor suppressor ELF. Oncogene 2006; 25: 693&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">16247473</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Mitra A, Li S et al. Targeting the E3 ubiquitin ligase PJA1 enhances tumor&#x2010;suppressing TGF&#x3b2; signaling. Cancer Res 2020; 80: 1819&#x2013;1832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7704101</ArticleId><ArticleId IdType="pubmed">32127355</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshiro K, Chen J, Srivastav J, Mishra L, Mishra B. Alterations in TGF&#x2010;&#x3b2; signaling leads to high HMGA2 levels potentially through modulation of PJA1/SMAD3 in HCC cells. Genes Cancer 2020; 11: 43&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289907</ArticleId><ArticleId IdType="pubmed">32577156</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin J, Mishra V, Glasgow E et al. PRAJA is overexpressed in glioblastoma and contributes to neural precursor development. Genes Cancer 2017; 8: 640&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5620009</ArticleId><ArticleId IdType="pubmed">28966725</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunda S, Heir P, Metcalf J et al. CIC protein instability contributes to tumorigenesis in glioblastoma. Nat Commun 2019; 10: 661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6368580</ArticleId><ArticleId IdType="pubmed">30737375</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieland I, Weidner C, Ciccone R et al. Contiguous gene deletions involving EFNB1, OPHN1, PJA1 and EDA in patients with craniofrontonasal syndrome. Clin Genet 2007; 72: 506&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">17941886</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T, Suzuki T, Raveau M et al. A recurrent PJA1 variant in trigonocephaly and neurodevelopmental disorders. Ann Clin Transl Neurol 2020; 7: 1117&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359110</ArticleId><ArticleId IdType="pubmed">32530565</ArticleId></ArticleIdList></Reference><Reference><Citation>Eck RJ, Kraemer BC, Liachko NF. Regulation of TDP&#x2010;43 phosphorylation in aging and disease. GeroScience 2021; 43: 1605&#x2013;1614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8492835</ArticleId><ArticleId IdType="pubmed">34032984</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruijs da Silva LA, Simonetti F, Hutten S et al. Disease&#x2010;linked TDP&#x2010;43 hyperphosphorylation suppresses TDP&#x2010;43 condensation and aggregation. EMBO J 2022; 41: e108443. 10.15252/embj.2021108443</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2021108443</ArticleId><ArticleId IdType="pmc">PMC9016352</ArticleId><ArticleId IdType="pubmed">35112738</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby J, Halligan E, Baptista MJ et al. Mutant SOD1 alters the motor neuronal transcriptome: Implications for familial ALS. Brain 2005; 128: 1686&#x2013;1706.</Citation><ArticleIdList><ArticleId IdType="pubmed">15872021</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Hu ZW, Mao CY, Shi CH, Xu YM. CHIP as a therapeutic target for neurological diseases. Cell Death Dis 2020; 11: 727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481199</ArticleId><ArticleId IdType="pubmed">32908122</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin Y, Klucken J, Patterson C, Hyman BT, McLean PJ. The co&#x2010;chaperone carboxyl terminus of Hsp70&#x2010;interacting protein (CHIP) mediates &#x3b1;&#x2010;synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem 2005; 280: 23727&#x2013;23734.</Citation><ArticleIdList><ArticleId IdType="pubmed">15845543</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, Kurisu J, Tateno M et al. CHIP promotes proteasomal degradation of familial ALS&#x2010;linked mutant SOD1 by ubiquitinating Hsp/Hsc70. J Neurochem 2004; 90: 231&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">15198682</ArticleId></ArticleIdList></Reference><Reference><Citation>Jana NR, Dikshit P, Goswami A et al. Co&#x2010;chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J Biol Chem 2005; 280: 11635&#x2013;11640.</Citation><ArticleIdList><ArticleId IdType="pubmed">15664989</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller VM, Nelson RF, Gouvion CM et al. CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J Neurosci 2005; 25: 9152&#x2013;9161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725774</ArticleId><ArticleId IdType="pubmed">16207874</ArticleId></ArticleIdList></Reference><Reference><Citation>Farina S, Esposito F, Battistoni M, Biamonti G, Francia S. Post&#x2010;translational modifications modulate proteinopathies of TDP&#x2010;43, FUS and hnRNP&#x2010;A/B in amyotrophic lateral sclerosis. Front Mol Biosci 2021; 8: 693325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8287968</ArticleId><ArticleId IdType="pubmed">34291086</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubenstein EM, Hochstrasser M. Redundancy and variation in the ubiquitin&#x2010;mediated proteolytic targeting of a transcription factor. Cell Cycle 2010; 9: 4282&#x2013;4285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3055181</ArticleId><ArticleId IdType="pubmed">20980825</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Masuda&#x2010;Suzukake M, Hasegawa M. Molecular mechanisms of the co&#x2010;deposition of multiple pathological proteins in neurodegenerative diseases. Neuropathology 2018; 38: 64&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">28948653</ArticleId></ArticleIdList></Reference><Reference><Citation>Coudert L, Nonaka T, Bernard E, Hasegawa M, Schaeffer L, Leblanc P. Phosphorylated and aggregated TDP&#x2010;43 with seeding properties are induced upon mutant huntingtin (mHtt) polyglutamine expression in human cellular models. Cell Mol Life Sci 2019; 76: 2615&#x2013;2632.</Citation><ArticleIdList><ArticleId IdType="pubmed">30863908</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewan R, Chia R, Ding J et al. Pathogenic huntingtin repeat expansions in patients with frontotemporal dementia and amyotrophic lateral sclerosis. Neuron 2021; 109: 448&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7864894</ArticleId><ArticleId IdType="pubmed">33242422</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Dixit VM. Drugging the undruggables: Exploring the ubiquitin system for drug development. Cell Res 2016; 26: 484&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4822129</ArticleId><ArticleId IdType="pubmed">27002218</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabrielsen M, Buetow L, Nakasone MA et al. A general strategy for discovery of inhibitors and activators of RING and U&#x2010;box E3 ligases with ubiquitin variants. Mol Cell 2017; 68: 456&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5655547</ArticleId><ArticleId IdType="pubmed">29053960</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt MF, Gan ZY, Komander D, Dewson G. Ubiquitin signalling in neurodegeneration: Mechanisms and therapeutic opportunities. Cell Death Differ 2021; 28: 570&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7862249</ArticleId><ArticleId IdType="pubmed">33414510</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>